MetaCap

AngioDynamics (ANGO) vs Sight Sciences (SGHT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Sight Sciences (SGHT) has outperformed AngioDynamics (ANGO) over the past year, gaining 40.2% versus a loss of 9.5%. Over five years, SGHT leads with a -46.7% price change compared with -60.3% for ANGO. Sight Sciences is the larger company by market cap ($565.8 million vs $454.6 million), about 1.2 times the size, while AngioDynamics is growing revenue faster (+9.5% vs -3.1%).

AngioDynamics converts more of its revenue into profit, with a net margin of -11.5% versus -49.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANGO-9.54%SGHT+40.22%
+57%-0%-58%
Nov 21, 20251 yearNov 20, 2026
ANGO-62.10%SGHT-49.55%
+8%-44%-97%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANGO versus SGHT key metrics
MetricANGOSGHT
Share price$10.81$10.18
Market cap$454.61M$565.79M
1-day change+0.46%-4.14%
YTD return-15.81%+28.37%
1-year return-9.54%+40.22%
5-year return-60.29%-46.67%
EPS (TTM)$-0.78$-0.52
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$320.17M$77.36M
Revenue growth (YoY)+9.46%-3.13%
Net income (latest FY)$-36.74M$-38.43M
Gross margin54.62%86.17%
Operating margin-12.47%-47.95%
Net margin-11.48%-49.67%
52-week high$16.29$11.60
52-week low$9.39$3.38
Distance from 52-week high-33.64%-12.20%
Analyst consensusnonebuy
Avg. price target upside+82.70%+20.33%
Average volume651.16K313.51K
Shares outstanding42.05M55.58M
Employees632186
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SGHT has outperformed ANGO by 49.8 percentage points over the past year.
  • AngioDynamics is more profitable, keeping -11.5 cents of every revenue dollar as net income versus -49.7 cents for Sight Sciences.
  • AngioDynamics grew revenue faster in its latest fiscal year (+9.46% vs -3.13%).

About AngioDynamics

ANGO stock →

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments.

Health Care · Medical/Dental Instruments · 632 employees

About Sight Sciences

SGHT stock →

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye.

Health Care · Medical/Dental Instruments · 186 employees

ANGO vs SGHT FAQ

Which is bigger, AngioDynamics or Sight Sciences?

Sight Sciences (SGHT) is larger, with a market capitalization of $565.79M compared with $454.61M for AngioDynamics (ANGO).

Which stock has performed better over the past year, ANGO or SGHT?

SGHT returned +40.22% over the past 12 months, compared with -9.54% for ANGO (price return, excluding dividends). Past performance does not predict future results.

Are AngioDynamics and Sight Sciences in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons